222 related articles for article (PubMed ID: 30068263)
1. Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS.
Qian X; Dimopoulos MA; Amatangelo M; Bjorklund C; Towfic F; Flynt E; Weisel KC; Ocio EM; Yu X; Peluso T; Sternas L; Zaki M; Moreau P; Thakurta A
Leuk Lymphoma; 2019 Feb; 60(2):462-470. PubMed ID: 30068263
[TBL] [Abstract][Full Text] [Related]
2. The clinical significance of cereblon expression in multiple myeloma.
Schuster SR; Kortuem KM; Zhu YX; Braggio E; Shi CX; Bruins LA; Schmidt JE; Ahmann G; Kumar S; Rajkumar SV; Mikhael J; Laplant B; Champion MD; Laumann K; Barlogie B; Fonseca R; Bergsagel PL; Lacy M; Stewart AK
Leuk Res; 2014 Jan; 38(1):23-8. PubMed ID: 24129344
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of pomalidomide in relapsed/refractory multiple myeloma in a "real-world" study: Polish Myeloma Group experience.
Charlinski G; Grzasko N; Jurczyszyn A; Janczarski M; Szeremet A; Waszczuk-Gajda A; Bernatowicz P; Swiderska A; Guzicka-Kazimierczak R; Lech-Maranda E; Szczepaniak A; Wichary R; Dmoszynska A
Eur J Haematol; 2018 Sep; 101(3):354-361. PubMed ID: 29882602
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Significance of Cereblon Expression in Patients With Multiple Myeloma.
Bila J; Sretenovic A; Jelicic J; Tosic N; Glumac I; Fekete MD; Antic D; Balint MT; Markovic O; Milojevic Z; Radojkovic M; Trajkovic G; Puric M; Pavlovic S; Mihaljevic B
Clin Lymphoma Myeloma Leuk; 2016 Nov; 16(11):610-615. PubMed ID: 27618360
[TBL] [Abstract][Full Text] [Related]
5. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.
Zhu YX; Braggio E; Shi CX; Bruins LA; Schmidt JE; Van Wier S; Chang XB; Bjorklund CC; Fonseca R; Bergsagel PL; Orlowski RZ; Stewart AK
Blood; 2011 Nov; 118(18):4771-9. PubMed ID: 21860026
[TBL] [Abstract][Full Text] [Related]
6. Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone.
Dimopoulos MA; Weisel KC; Song KW; Delforge M; Karlin L; Goldschmidt H; Moreau P; Banos A; Oriol A; Garderet L; Cavo M; Ivanova V; Alegre A; Martinez-Lopez J; Chen C; Spencer A; Knop S; Bahlis NJ; Renner C; Yu X; Hong K; Sternas L; Jacques C; Zaki MH; San Miguel JF
Haematologica; 2015 Oct; 100(10):1327-33. PubMed ID: 26250580
[TBL] [Abstract][Full Text] [Related]
7. Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma.
Zhu YX; Braggio E; Shi CX; Kortuem KM; Bruins LA; Schmidt JE; Chang XB; Langlais P; Luo M; Jedlowski P; LaPlant B; Laumann K; Fonseca R; Bergsagel PL; Mikhael J; Lacy M; Champion MD; Stewart AK
Blood; 2014 Jul; 124(4):536-45. PubMed ID: 24914135
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma.
Zhu YX; Kortuem KM; Stewart AK
Leuk Lymphoma; 2013 Apr; 54(4):683-7. PubMed ID: 22966948
[TBL] [Abstract][Full Text] [Related]
9. Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma.
San Miguel JF; Weisel KC; Song KW; Delforge M; Karlin L; Goldschmidt H; Moreau P; Banos A; Oriol A; Garderet L; Cavo M; Ivanova V; Alegre A; Martinez-Lopez J; Chen C; Renner C; Bahlis NJ; Yu X; Teasdale T; Sternas L; Jacques C; Zaki MH; Dimopoulos MA
Haematologica; 2015 Oct; 100(10):1334-9. PubMed ID: 26160879
[TBL] [Abstract][Full Text] [Related]
10. Pomalidomide in heavily pretreated refractory multiple myeloma: a case report.
Palmas A; Piras G; Uras A; Asproni R; Murineddu M; Monne M; Stradoni R; Latte G
Future Oncol; 2017 Feb; 13(5s):7-9. PubMed ID: 28116939
[TBL] [Abstract][Full Text] [Related]
11. Expression, mutation, and methylation of cereblon-pathway genes at pre- and post-lenalidomide treatment in multiple myeloma.
Tachita T; Kinoshita S; Ri M; Aoki S; Asano A; Kanamori T; Yoshida T; Totani H; Ito A; Kusumoto S; Komatsu H; Yamagata K; Kubo K; Tohkin M; Fukuda S; Iida S
Cancer Sci; 2020 Apr; 111(4):1333-1343. PubMed ID: 32061138
[TBL] [Abstract][Full Text] [Related]
12. Thalidomide-based induction regimens are as effective as bortezomib-based regimens in elderly patients with multiple myeloma with cereblon expression.
Jung SH; Choi HJ; Shin MG; Lee SS; Hwang EC; Jung TY; Cho MS; Yang DH; Ahn JS; Kim YK; Kim HJ; Lee JJ
Ann Hematol; 2016 Oct; 95(10):1645-51. PubMed ID: 27365142
[TBL] [Abstract][Full Text] [Related]
13. Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma.
Dimopoulos K; Fibiger Munch-Petersen H; Winther Eskelund C; Dissing Sjö L; Ralfkiaer E; Gimsing P; Grønbaek K
Leuk Lymphoma; 2019 Jan; 60(1):180-188. PubMed ID: 29718735
[TBL] [Abstract][Full Text] [Related]
14. Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma.
Fouquet G; Pegourie B; Macro M; Petillon MO; Karlin L; Caillot D; Roussel M; Arnulf B; Mathiot C; Marit G; Kolb B; Stoppa AM; Brechiniac S; Richez V; Rodon P; Banos A; Wetterwald M; Garderet L; Royer B; Hulin C; Benbouker L; Decaux O; Escoffre-Barbe M; Fermand JP; Attal M; Avet-Loiseau H; Moreau P; Facon T; Leleu X;
Ann Oncol; 2016 May; 27(5):902-7. PubMed ID: 26787238
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, safety, and cost of pomalidomide in relapsed and refractory multiple myeloma.
Gueneau P; Chretien ML; Cransac-Miet A; Aho LS; Lafon I; Favennec C; Guy J; Caillot D; Boulin M
Eur J Haematol; 2018 May; 100(5):518-525. PubMed ID: 29393533
[TBL] [Abstract][Full Text] [Related]
16. Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma.
Weisel KC; Dimopoulos MA; Moreau P; Lacy MQ; Song KW; Delforge M; Karlin L; Goldschmidt H; Banos A; Oriol A; Alegre A; Chen C; Cavo M; Garderet L; Ivanova V; Martinez-Lopez J; Knop S; Yu X; Hong K; Sternas L; Jacques C; Zaki MH; San Miguel J
Haematologica; 2016 Jul; 101(7):872-8. PubMed ID: 27081177
[TBL] [Abstract][Full Text] [Related]
17. Do baseline Cereblon gene expression and IL-6 receptor expression determine the response to thalidomide-dexamethasone treatment in multiple myeloma patients?
Bedewy AM; El-Maghraby SM
Eur J Haematol; 2014 Jan; 92(1):13-8. PubMed ID: 24118365
[TBL] [Abstract][Full Text] [Related]
18. Pomalidomide experience: an effective therapeutic approach with immunomodulatory drugs in a patient with relapsed-refractory multiple myeloma.
Conticello C; Parisi M; Romano A; Calafiore V; Ancora F; La Fauci A; Consoli ML; Di Raimondo F
Future Oncol; 2017 Feb; 13(5s):3-6. PubMed ID: 28116941
[TBL] [Abstract][Full Text] [Related]
19. Pomalidomide-dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial.
Ailawadhi S; Mikhael JR; LaPlant BR; Laumann KM; Kumar S; Roy V; Dingli D; Bergsagel PL; Buadi FK; Rajkumar SV; Fonseca R; Gertz MA; Kapoor P; Sher T; Hayman SR; Stewart AK; Dispenzieri A; Kyle RA; Gonsalves WI; Reeder CB; Lin Y; Go RS; Leung N; Kourelis T; Lust JA; Russell SJ; Chanan-Khan AA; Lacy MQ
Leukemia; 2018 Mar; 32(3):719-728. PubMed ID: 28860655
[TBL] [Abstract][Full Text] [Related]
20. High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance.
Broyl A; Kuiper R; van Duin M; van der Holt B; el Jarari L; Bertsch U; Zweegman S; Buijs A; Hose D; Lokhorst HM; Goldschmidt H; Sonneveld P; ;
Blood; 2013 Jan; 121(4):624-7. PubMed ID: 23233657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
